DUSA Pharmaceuticals
| Type | Subsidiary |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1991 |
| Founder | D. Geoffrey Shulman |
| Defunct | 2012 |
| Fate | Acquired by Sun Pharmaceutical |
| Successor | DUSA Dermatology |
| Headquarters | , United States |
Area served | United States |
| Products | Dermatological pharmaceuticals and treatments |
| Owner | Sun Pharmaceutical |
| Website | www |
DUSA Pharmaceuticals, Inc. was an American pharmaceutical company specializing in dermatological products and treatments. It was founded in 1991 by Canadian dermatologist and pharmaceutical executive D. Geoffrey Shulman, who served as the company's chairman, president and chief executive officer.
The company developed Levulan photodynamic therapy, a treatment using aminolevulinic acid. In 1999, Levulan became the first topical photodynamic therapy approved in the United States for the treatment of actinic keratosis. DUSA's products also included Nicomide.
DUSA was acquired by Caraco Pharmaceutical Laboratories, a subsidiary of Sun Pharmaceutical, in 2012. Its products continued to be marketed under the DUSA Dermatology name.